Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review

Version 1 : Received: 12 January 2024 / Approved: 15 January 2024 / Online: 15 January 2024 (20:55:55 CET)

A peer-reviewed article of this Preprint also exists.

Sechi, I.; Muresu, N.; Di Lorenzo, B.; Saderi, L.; Puci, M.; Aliberti, S.; Maida, I.; Mondoni, M.; Piana, A.; Sotgiu, G. Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review. Infect. Dis. Rep. 2024, 16, 200-215. Sechi, I.; Muresu, N.; Di Lorenzo, B.; Saderi, L.; Puci, M.; Aliberti, S.; Maida, I.; Mondoni, M.; Piana, A.; Sotgiu, G. Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review. Infect. Dis. Rep. 2024, 16, 200-215.

Abstract

Recurrent respiratory papillomatosis (RRP) is a non- malignant disease, characterized by the production of wart-like growths in respiratory tract, affecting both young and adults (Juvenile-Onset Recurrent Respiratory Papillomatosis, JORRP and Adult-Onset Recurrent Respiratory Papillomatosis, AORRP, respectively). Infection caused by Human Papillomavirus (HPV) is known as the main factors involved in RRP development. Complications of RRP may rarely occur, including lung involvement and malignant transformation. The present systematic review was aimed to evaluate the prevalence of severe complications, as lung involvement and lung tumor in JORRP and AORRP patients, following the guideline for reporting systematic reviews and meta-analysis (PRISMA Statement). Among the 378 studies were found on PubMed and Scopus using the following MESH terms “recurrent respiratory papillomatosis and lung tumor” and “pulmonary tumor and recurrent respiratory papillomatosis”. Basing on inclusion and exclusion criteria, a total of 11 studies were included in the systematic review. We found a pooled prevalence of 8% (95% CI:4%-14%; I2: 87.5%) for lung involvement in RRP patients. In addition, we found a pooled risk difference of 5% in lung involvement between JORRP and AORRP (95% CI: -7%-18%; I2 :85.6%, p-value: 0.41). Among patients with lung involvement, we observed a pooled prevalence of lung tumor of 4% (95% CI:1%- 7%; I2: 67.1%), and a pooled prevalence mortality for this group of 4% (95% CI:2%-6%; I2: 0%). Overall, the positivity rate for HPV-6 and -11 in patients with RRP was 91%. Considering only cases with pulmonary involvement, the pooled prevalence for HPV 11 was 21% (95% CI: 5%-45%; I2: 77.2%). Our results evidenced a low/middle risk of pulmonary involvement and lung tumor in JORRP and AORRP patients, with an increased risk for HPV-11 positive patients. Further studies should be performed to improve knowledge and adopt preventive measures to contrast the progression to severe diseases in RRP patients.

Keywords

Recurrent Respiratory Papillomatosis, HPV, Lung cancer, Lung Involvement, Pulmonary involvement.

Subject

Public Health and Healthcare, Public Health and Health Services

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.